GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

baxdrostat   Click here for help

GtoPdb Ligand ID: 12362

Synonyms: Baxfendy® | CIN-107 | CIN107 | RO6836191
Approved drug
baxdrostat is an approved drug
Compound class: Synthetic organic
Comment: Baxdrostat (CIN-107, formerly RO6836191 [1]) is a selective, oral aldosterone synthase (CYP11B2) inhibitor. It inhibits aldosterone biosynthesis but does not alter plasma cortisol, which demonstrates its selectivity for CYP11B2 [4]. Baxdrostat is being developed by CinCor Pharma as a potential intervention for treatment resistant hypertension.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

baxdrostat is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 62.3
Molecular weight 363.19
XLogP 2.31
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCC(=O)N[C@@H]1CCCc2c1cncc2c1ccc2c(c1)CCC(=O)N2C
Isomeric SMILES CCC(=O)N[C@@H]1CCCc2c1cncc2c1cc2c(cc1)N(C(=O)CC2)C
InChI InChI=1S/C22H25N3O2/c1-3-21(26)24-19-6-4-5-16-17(12-23-13-18(16)19)14-7-9-20-15(11-14)8-10-22(27)25(20)2/h7,9,11-13,19H,3-6,8,10H2,1-2H3,(H,24,26)/t19-/m1/s1
InChI Key VDEUDSRUMNAXJG-LJQANCHMSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Baxdrostat (CIN-107) was progressed to clinical evaluation. It was investigated in patients with uncontrolled or treatment-resistant hypertension [3], or for potential to reduce aldosterone levels in patients with primary aldosteronism/hyperaldosteronism. Pharmacokinetics and safety data from a phase 1 trial in healthy volunteers were published in January 2023 [4]. The baxdrostat hypertension Phase 3 program has 3 trial components [2]. First approval was granted by the US FDA in May 2026, to treat hypertension in combination with other antihypertensive drugs.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05432167 A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease Phase 2 Interventional CinCor Pharma, Inc.
NCT04605549 A Study of CIN-107 in Adults With Primary Aldosteronism Phase 2 Interventional CinCor Pharma, Inc.
NCT05137002 A Study of CIN-107 in Patients With Uncontrolled Hypertension Phase 2 Interventional CinCor Pharma, Inc.
NCT06034743 A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Phase 3 Interventional AstraZeneca Known as the BaxHTN Phase III trial. 2
NCT06168409 A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension Phase 3 Interventional AstraZeneca 2
NCT06344104 A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Phase 3 Interventional AstraZeneca